Novartis quietly hands topical treatment for rare disease to LifeMax — latest in a string of out-licensing deals
The steady stream of outward deals flowing from Novartis made a rare disease turn today.
Palo Alto-based LifeMax Laboratories has licensed BPR277, a clinical stage ointment that treats a rare condition affecting the skin, hair and immune systems called Netherton syndrome. Caused by mutations in the SPINK5 gene, the disease can be life-threatening for newborns. Current treatments consist of various topical relief products and antibiotics with no FDA-approved products targeting the disease itself.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.